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T
he evidence is now compelling that an excess
supply of fatty acids, beyond that required for
energy needs, is a cause of muscle insulin resis-
tance. Intramyocellular triglyceride accumula-
tion is a marker of excess fatty acid supply to muscle, and
it is now two decades since an association was recognized
between intramyocellular triglyceride accumulation and
insulin resistance (1). Arguably, the major issues now (2,3)
are to ﬁrst pin down the causal mechanisms between fatty
acid oversupply and insulin resistance (the prevailing view
is that triglycerides themselves do not cause insulin resis-
tance because they localize within discrete lipid droplets),
second, deﬁne and develop appropriate therapeutic strat-
egies, and third, clarify the place of dysregulated lipid
metabolism against other, not necessarily mutually exclu-
sive, putative causes of insulin resistance (4).
In this issue of Diabetes, Wang et al. (5) have generated
a novel skeletal muscle–speciﬁc lipoprotein lipase knock-
out
/mouse line (SMLPL
/) to better understand how
lipid-derived signals integrate with insulin signaling and
how reducing skeletal muscle lipoprotein lipase affects
systemic fatty acid partitioning and insulin sensitivity. The
studies clearly support the view that partitioning fat away
from skeletal muscle reduces muscle triglyceride content
and improves insulin sensitivity. This result is hardly
surprising given the plethora of genetic and nutritional
evidence showing that manipulation of fatty acid supply to
muscle produces reciprocal changes in insulin sensitivity
(2,3). For example, mice with genetically enhanced muscle
lipoprotein lipase expression exhibit insulin resistance (6).
However, Wang et al. were able to show that the downside
of partitioning lipids away from muscle was that other
tissues pay a considerable cost: the heart, liver, and
adipose tissue all become insulin resistant and would most
likely accumulate excessive lipids with time.
Wang et al. report a relatively mild phenotype in young
SMLPL
/ mice. They were not obese, and plasma glu-
cose, insulin, free fatty acid (FFA), and metabolic hor-
mones were largely unaffected. Circulating triglycerides
trended higher in the SMLPL
/ mice, stressing the impor-
tance of VLDL-triglyceride as a source of fatty acids for
muscle but also pointing to an important contribution
from skeletal muscle lipoprotein lipase action in regulating
systemic triglyceride concentrations. Although whole-
body insulin sensitivity was unaffected in young mice,
closer examination using radiolabeled tracers revealed
that skeletal muscle insulin sensitivity was enhanced,
whereas white adipose tissue, heart, and hepatic insulin
sensitivity were blunted, all by 50% or more—albeit with-
out evidence of defective insulin signaling. Regarding
skeletal muscle, the maneuver of restricting muscle fatty
acid supply enhanced insulin sensitivity and was accom-
panied by enhanced insulin signaling, as indicated by
increased Akt phosphorylation under insulin stimulation.
This latter ﬁnding is important because it suggests that the
increased insulin-mediated muscle glucose uptake is not
just a result of substrate competition (i.e., adjustment of
the glucose–fatty acid cycle favoring glucose metabolism).
Nevertheless, the precise mediators of the increased mus-
cle insulin sensitivity are obscure; the usual culprits linked
to impaired insulin signaling when cytosolic lipids are
increased include ceramides (7), diglycerides (8), and
long-chain fatty acyl-coenzyme A (9); however, here they
are not altered from control levels. It may be that cellular
location of one or more of these species will prove
important. Alternatively, others have suggested that mito-
chondrial lipid overload yields incomplete fat oxidation,
mitochondrial distress, and insulin resistance by mecha-
nisms that have not yet been deﬁned (10). Whether any of
these putative mechanisms are associated with the con-
verse case of enhanced muscle insulin sensitivity above
that in normal wild-type animals, as reported here in
SMLPL
/ mice, is uncertain. One suspects this feat will
not be very easy to achieve without, for example, some-
thing like an exercise training regimen.
Further phenotypic evaluation by Wang et al. (5) re-
vealed that SMLPL
/ mice were more prone to obesity
induced by high-fat feeding and aging, highlighting a
common requirement to superimpose metabolic stress on
rodent models to bring out marked phenotypic changes.
Unfortunately, high-fat–fed and aged mice were not stud-
ied in the same detail as the young mice; e.g., although the
young SMLPL
/ mice showed rates of energy expenditure
similar to those of controls, this parameter needs to be
examined with obesity onset. Nevertheless, the slow pro-
gression of obesity commencing from a state of selective
extramuscle insulin resistance may prove a useful model
to study mechanisms.
The Wang et al. (5) study highlights the importance of an
often-forgotten potential source of muscle fatty acid over-
supply: that derived from local lipolysis of lipoprotein-
derived triglycerides mediated by lipoprotein lipase (11).
Overexpression of lipoprotein lipase in either muscle
(6,12) or liver (6) results in signiﬁcantly increased local
storage of triglyceride. Although the excess systemic fatty
acids is commonly attributed to defective adipose tissue
lipolysis and greater fatty acid release into the blood (13),
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resistance is controversial, particularly in the presence of
elevated fasting insulin levels (14). High VLDL-triglyceride
levels may be more characteristic of human insulin resis-
tance than altered FFA output (12).
The study by Want et al. raises several other major,
unresolved questions. First, it remains unclear how lipid-
derived signals integrate with insulin signaling in the
SMLPL
/ model. What are the signaling pathways under-
pinning insulin resistance in the liver and adipose tissue
when cellular lipid levels, inﬂammatory markers, and
insulin signal transduction are not perturbed? Is it possible
that signaling downstream from Akt, such as AS160/
TBC1D4 activation or even Akt localization, could affect
the observed biological responses (15)? Second, is the
reduction in muscle triglyceride in SMLPL
/ mice simply
mediated by reduced FFA uptake from lipoprotein triglyc-
erides, or is fatty acid oxidation or intracellular triglycer-
ide lipase action also enhanced? Given that peroxisome
proliferator–activated receptor  coactivator 1 (PGC1)-
mRNA was elevated in SMLPL
/ muscle and that PGC1
transcriptional coactivators are major regulators of sev-
eral metabolic pathways (16), the potential for the integra-
tion of metabolic signals requires further study in these
mice. Third, the fate of the excess triglyceride-derived
fatty acids is unknown. Presumably, there is a slow
accumulation in adipose and heart over time, and the
study of detailed lipid turnover kinetics will be required to
address this issue. Finally, an intriguing observation is the
profound cardiac insulin resistance in SMLPL
/ mice that
occurs in the absence of enhanced lipoprotein lipase
activity or cardiomyopathy. In this regard, the heart exhib-
its an amazing potential to shift between metabolic sub-
strate, and the reduced insulin-stimulated glucose uptake
may simply result from greater triglyceride-derived fatty
acids and energy substrate competition (i.e., glucose–fatty
acid cycle effect).
Perhaps the major unanswered question of clinical
relevance is whether providing metabolic relief by direct-
ing fat away from one tissue is a sound approach for the
treatment of obesity-related disorders, such as muscle
insulin resistance, or whether the ultimate fate will always
be compensatory storage in other tissues and the induc-
tion of secondary complications. In the end, is such a
therapeutic approach just a classic case of robbing Peter
to pay Paul?
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